Navigation Links
Hologic Introduces Synthesized 2D Image Algorithm Designed to Eliminate the Need for a 2D Mammogram in a 2D plus 3D Tomosynthesis Exam
Date:11/27/2011

BEDFORD, Mass., Nov. 27, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the commercial release of its C-View synthesized 2D image reconstruction algorithm that eliminates the need for a conventional 2D mammogram as a component of a tomosynthesis (3D mammography) breast cancer screening exam. C-View software is approved for sale throughout the European Economic Area and in other countries recognizing the CE Mark.

For users of Hologic's 2D plus 3D tomosynthesis breast cancer screening system, C-View software creates a 2D image from a single tomosynthesis scan and eliminates the need for the acquisition of additional 2D exposures.

Dr. Stephen Rose, a board certified radiologist with Houston Breast Imaging, one of the first U.S. radiologists to adopt breast tomosynthesis, stated "Hologic's synthesized 2D image reconstruction algorithm is very impressive. C-View provides the information contained in a conventional 2D mammogram without the need for additional exposures while maintaining the superior clinical performance of Hologic's combo-mode (2D plus 3D) imaging."

Hologic is featuring the new algorithm along with the Company's Selenia Dimensions breast tomosynthesis system at the Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA), the largest radiology show in the world, taking place at McCormick Place in Chicago November 26 through December 2.

Hologic is the global market leader in breast tomosynthesis (3D mammography) with its Selenia Dimensions platform. In Hologic's clinical studies, radiologists reading in combo-mode (2D plus 3D) compared to 2D mammography alone demonstrated superior clinical performance in ruling out breast cancer without recalling the patient for further study and the proportion of mammograms with cancer which were correctly diagnosed.

About Hologic, Inc.Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, breast magnetic resonance imaging, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia and uterine fibroids, permanent contraception, osteoporosis assessment, preterm birth risk assessment, mini C-arm for extremity imaging and molecular diagnostic products including HPV and reagents for a variety of DNA and RNA analysis applications. For more information, visit www.hologic.com.

Hologic, C-View, Dimensions and Selenia are trademarks and/or registered trademarks of Hologic, Inc, and/or its subsidiaries in the United States and/or other countries.

Forward Looking Statement DisclaimerThis News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use of Hologic products. There can be no assurance that the C-View synthesized 2D image reconstruction algorithm when used with a Selenia Dimensions breast tomosynthesis system will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to the data or statements presented herein to reflect any change in the Company's expectations or any change in events, conditions or circumstances on which any such data or statements are based.Contacts:Olga Karagiannis

 

Jim Culley, PhDCorporate Marketing

 

Corporate MarketingHologic, Inc.

 

Hologic, Inc.Tel: 781.761.7069

Olga.karagiannis@hologic.com

 

Tel: 781.999.7583

Jim.culley@hologic.com


'/>"/>

SOURCE Hologic, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Year Analysis of Treatment Efficacy, Cosmesis, and Toxicity Support use of the Hologic Mammosite Radiation Therapy System
2. ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrigs Disease
3. Hologic Releases the Results of the Cervista(TM) HPV Clinical Trials
4. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
5. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
6. Hologic Receives CE Marking for the ThinPrep(R) Integrated Imager
7. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
8. Hologic Expands Healthcare Investment in Asia
9. Hologic to Host Investor Reception at RSNA 2009
10. Hologic to Present at Citis 2009 Sixth Annual Small/Mid Cap Conference
11. Hologic Announces Fourth Quarter and Fiscal 2009 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin ... companies that call for a minimum wage raise to $12 an hour by 2020 and ... This will restore the lost value of the minimum wage, assure the wage floor does ...
(Date:6/24/2016)... ... 24, 2016 , ... EB Medicine presented its first-ever “Issue ... conference in Ponte Vedra Beach, FL. The awards honor the outstanding work of ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the ...
Breaking Medicine News(10 mins):